1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Potassium Channel

Potassium Channel

KcsA

Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. They form potassium-selective pores that span cell membranes. Potassium channels are found in most cell types and control a wide variety of cell functions. Potassium channels function to conduct potassium ions down their electrochemical gradient, doing so both rapidly and selectively. Biologically, these channels act to set or reset the resting potential in many cells. In excitable cells, such asneurons, the delayed counterflow of potassium ions shapes the action potential. By contributing to the regulation of the action potential duration in cardiac muscle, malfunction of potassium channels may cause life-threatening arrhythmias. Potassium channels may also be involved in maintaining vascular tone.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-116478
    L-3373
    Inhibitor
    L-3373 is a voltage-dependent potassium channel inhibitor with activity that reduces the effective refractory period and the dispersion of monophasic action potential duration, while significantly reducing susceptibility to ventricular fibrillation in a cat model of left ventricular hypertrophy.
    L-3373
  • HY-19397
    BMS-223131
    Activator
    BMS-223131 (Compound 1) is a potent maxi-K potassium channel opener. BMS-223131 has a strong inhibitory effect on the CYP2C9 enzyme (IC50 = 1.7 μM) and also shows varying degrees of inhibition on other common CYP enzymes such as CYP1A2, CYP2C19, CYP2D6, and CYP3A4. BMS-223131 can enhance the outward current mediated by maxi-K, by promoting K+ efflux to hyperpolarize the cell membrane and reducing Ca2+ influx. BMS-223131 can be used for the research of neurological disease, such as stroke.
    BMS-223131
  • HY-19244
    JTV-506
    Activator
    JTV-506 is a potent ATP-sensitive potassium channel opener. JTV-506 inhibits Histamine (HY-B1204)-induced contraction of tracheal smooth muscle by activation of KATP channels. JTV-506 attenuates pulmonary vascular tone through its direct action on vascular smooth muscle cells. JTV-506 can be used for pulmonary hypertension research[1][2].
    JTV-506
  • HY-P1426A
    AmmTX3 TFA
    Inhibitor
    AmmTX3 TFA is a peptide toxin that can be isolated from the venom of the scorpion Androctonus mauretanicus. AmmTX3 TFA is specific blocker of Kv4 channel. AmmTX3 TFA inhibits the A-type K+ current (Ki: 131 nM).
    AmmTX3 TFA
  • HY-116556
    Rilmakalim
    Activator
    Rilmakalim (HOE 234) is a potassium channel opener (PCO) that activates ATP-sensitive K+ channels in the heart or other tissues.
    Rilmakalim
  • HY-14186
    KVI-020
    Inhibitor
    KVI-020 is an orally active, potent and selective blocker of the atrial potassium channel Kv1.5, with an IC50 of 480 nM. KVI-020 can inhibits hERG, with an IC50 of 15100 nM. KVI-020 is a potent antiarrhythmic agent, and can be used for atrial fibrillation (AF) research.
    KVI-020
  • HY-B0401S1
    Tolbutamide-13C
    Inhibitor
    Tolbutamide-13C is the 13C-labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic agent.
    Tolbutamide-<sup>13</sup>C
  • HY-121183
    Aprikalim
    Activator
    Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes. Using patch-clamp techniques, it was found that aprikalim enhances KATP channel activity more effectively in Mg-NDP solution compared to standard solutions. In Mg-NDP solution, aprikalim reduced the sensitivity of KATP channels to ATP, increasing the concentration of ATP required to inhibit channel activity by half (K1) from 56 μM to 180 μM. However, this effect diminished over time. Aprikalim's ability to activate KATP channels in Mg-NDP solution suggests potential therapeutic implications in modulating cardiac excitability and may relate to changes in channel protein enzymatic activity under experimental conditions.
    Aprikalim
  • HY-175289
    hERG-IN-3
    Inhibitor
    hERG-IN-3 is an orally active hERG blocker with an IC50 of 44.5 nM. hERG-IN-3 exhibits a Ki for β2-adrenergic receptor of 14 nM. hERG-IN-3 exhibits the skeletal muscle Nav1.4 and sodium channel-blocking activities (IC50 = 4.4 μM, 3-fold increasement than hNav1.5). hERG-IN-3 displays a potent antimyotonic activity in an animal model. hERG-IN-3 can be used for the study of Myotonia Congenita.
    hERG-IN-3
  • HY-118387
    AVE-0118
    Inhibitor
    AVE-0118 is a nonselective Kv1.5 blocker with an IC50 of 1.1 μM. AVE-0118 is a multichannel inhibitor with weak, micromolar activity against Kv1.5 and other ion channels. It is inactive against IKs, IKATP, and L-type Ca+ channels.
    AVE-0118
  • HY-W415121R
    Bupivacaine hydrochloride monohydrate (Standard)
    Inhibitor
    Bupivacaine (hydrochloride monohydrate) (Standard) is the analytical standard of Bupivacaine (hydrochloride monohydrate). This product is intended for research and analytical applications. Bupivacaine hydrochloride monohydrate is a NMDA receptor inhibitor. Bupivacaine hydrochloride monohydrate can block sodium, L-calcium, and potassium channels. Bupivacaine hydrochloride monohydrate potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride monohydrate can be used for the research of chronic pain.
    Bupivacaine hydrochloride monohydrate (Standard)
  • HY-B1751D
    Quinidine sulfate dihydrate
    Inhibitor
    Quinidine sulfate dihydrate is an antiarrhythmic agent. Quinidine sulfate dihydrate is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine sulfate dihydrate is also a K+ channel blocker with an IC50 of 19.9 μM, and can induce apoptosis. Quinidine sulfate dihydrate can be used for malaria research.
    Quinidine sulfate dihydrate
  • HY-P1282
    Agitoxin-2
    Inhibitor
    Agitoxin-2 is a K+ channel inhibitor, with IC50 values of 201 pM and 144 pM for mKV1.3 and mKV1.1, respectively).
    Agitoxin-2
  • HY-126123
    NR2B-selective NMDA receptor antagonist 1
    Inhibitor
    NR2B-selective NMDA receptor antagonist 1 (compound 29) is a potent antagonist of NR1/NR2B receptors, with IC50s of 0.05 μM, 0.73 μM, 2.4 μM to NR1/NR2B NMDA receptor, hERG, α1-AdR, respectivity. NR2B-selective NMDA receptor antagonist 1 exhibites efficient permeability across the blood–brain barrier.
    NR2B-selective NMDA receptor antagonist 1
  • HY-172933
    Nav1.8 modulator 1
    Modulator
    Nav1.8 modulator 1 (compound 1) is a potent Nav1.8 modulator. Nav1.8 modulator 1 has the potential for pain research.
    Nav1.8 modulator 1
  • HY-101433
    N-Acetylprocainamide hydrochloride
    Inhibitor 99.83%
    N-Acetylprocainamide (Acecainide) hydrochloride is a class III antiarrhythmic, which blocks K+ channels. N-Acetylprocainamide hydrochloride exerts inhibitory effects on the maximum following frequency (MFF) of isolated rabbit atria. N-Acetylprocainamide hydrochloride can be used for the study of arrhythmias.
    N-Acetylprocainamide hydrochloride
  • HY-172141
    Ebio2
    Activator
    Ebio2 is a potent KCNQ2 activator.
    Ebio2
  • HY-111245
    AZD-1305
    Inhibitor
    AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research.
    AZD-1305
  • HY-118328
    Hymenidin
    Inhibitor
    Hymenidin is a natural antagonist of serotonergic receptor and inhibitor of voltage-gated potassium channels. Hymenidin also induces cancer cell apoptosis.
    Hymenidin
  • HY-113147AR
    L-Palmitoylcarnitine chloride (Standard)
    Inhibitor
    L-Palmitoylcarnitine (chloride) (Standard) is the analytical standard of L-Palmitoylcarnitine (chloride). This product is intended for research and analytical applications. L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].
    L-Palmitoylcarnitine chloride (Standard)
Cat. No. Product Name / Synonyms Application Reactivity